Robert Gagnon
About
Robert Gagnon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Robert Gagnon has authored 49 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Robert Gagnon's work include HER2/EGFR in Cancer Research (12 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Renal cell carcinoma treatment (7 papers). Robert Gagnon is often cited by papers focused on HER2/EGFR in Cancer Research (12 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Renal cell carcinoma treatment (7 papers). Robert Gagnon collaborates with scholars based in United States, United Kingdom and Italy. Robert Gagnon's co-authors include David M. Mannino, Thomas L. Petty, Eva Lydick, Frank C. Barone, Raymond F. White, Tianli Yue, Giora Feuerstein, Xinkang Wang, Sergei Leonov and Tona M. Gilmer and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.
In The Last Decade
Robert Gagnon
49 papers receiving 2.5k citations
Hit Papers
Peers
Robert Gagnon
Jie Cai China
T. Jeroen N. Hiltermann Netherlands
Jan DʼHaese Germany
Ming Lu China
Steven A. Bigler United States
Chikuma Hamada Japan
Syed A. Hussain United Kingdom
Kouji Izumi Japan
Liping Du China
Nobumichi Tanaka Japan
Citations per year, relative to Robert Gagnon Robert Gagnon (= 1×)
peers
Jie Cai
Countries citing papers authored by Robert Gagnon
Since
Specialization
Citations
This map shows the geographic impact of Robert Gagnon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Gagnon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Gagnon more than expected).
Fields of papers citing papers by Robert Gagnon
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert Gagnon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Gagnon. The network helps show where Robert Gagnon may publish in the future.
Co-authorship network of co-authors of Robert Gagnon
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Gagnon. A scholar is included among the top collaborators of Robert Gagnon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Gagnon. Robert Gagnon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gan, Hui, Michael Millward, Mathilde Jalving, et al.. (2021). A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. The Oncologist. 26(10). e1844–e1853.
2.
Angevin, Eric, Stefanie L. Groenland, Todd M. Bauer, et al.. (2020). 11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study. Annals of Oncology. 31. S3–S3.
3.
Palmer, Scott M., Laurie D. Snyder, Jamie L. Todd, et al.. (2018). Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. CHEST Journal. 154(5). 1061–1069.
4.
Robertson, Alan S., Mark J. Majchrzak, Robert Gagnon, et al.. (2017). Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents. Neuromuscular Disorders. 27(7). 635–645.
5.
Yau, Thomas, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.. (2016). A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 23(10). 2405–2413.
6.
Santiago-Walker, Ademi, Robert Gagnon, Jolly Mazumdar, et al.. (2015). Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research. 22(3). 567–574.
7.
Choueiri, Toni K., David J. Figueroa, André P. Fay, et al.. (2014). Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clinical Cancer Research. 21(5). 1071–1077.
8.
Choueiri, Toni K., André P. Fay, Robert Gagnon, et al.. (2013). The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. Clinical Cancer Research. 19(18). 5218–5226.
9.
Iwata, Hiroji, Hirofumi Fujii, Norikazu Masuda, et al.. (2013). Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. Breast Cancer. 22(2). 192–200.
10.
Shah, Manish A., Zev A. Wainberg, Daniel V.T. Catenacci, et al.. (2013). Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE. 8(3). e54014–e54014.
11.
Lipton, Allan, Kim Leitzel, Suhail M. Ali, et al.. (2011). Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression‐free survival in patients with HER2‐positive metastatic breast cancer receiving lapatinib monotherapy. Cancer. 117(21). 5013–5020.
12.
Scaltriti, Maurizio, Sarat Chandarlapaty, Ludmila Prudkin, et al.. (2010). Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research. 16(9). 2688–2695.
13.
Toi, Masakazu, Hiroji Iwata, Yasuhiro Fujiwara, et al.. (2009). Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. British Journal of Cancer. 101(10). 1676–1682.
14.
Cecchi, Franco, Robert Gagnon, Howard Kallender, et al.. (2009). Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients. Molecular Cancer Therapeutics. 8(12_Supplement). B210–B210.
15.
Press, Michael F., Richard S. Finn, David Cameron, et al.. (2008). HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clinical Cancer Research. 14(23). 7861–7870.
16.
Jc, Lee, Peter Pommerville, Gerald Brock, et al.. (2006). Physician‐rated patient preference and patient‐ and partner‐rated preference for tadalafil or sildenafil citrate: results from the Canadian ‘Treatment of Erectile Dysfunction’ observational study. British Journal of Urology. 98(3). 623–629.
17.
Newman, Roland, Kandasamy Hariharan, Mitchell E. Reff, et al.. (2001). Modification of the Fc Region of a Primatized IgG Antibody to Human CD4 Retains Its Ability to Modulate CD4 Receptors but Does Not Deplete CD4+ T Cells in Chimpanzees. Clinical Immunology. 98(2). 164–174.
18.
Mannino, David M., Robert Gagnon, Thomas L. Petty, & Eva Lydick. (2000). Obstructive Lung Disease and Low Lung Function in Adults in the United States. Archives of Internal Medicine. 160(11). 1683–1683.
19.
Gagnon, Robert, et al.. (1998). Estimation of Confidence Intervals for Area Under the Curve from Destructively Obtained Pharmacokinetic Data. Journal of Pharmacokinetics and Biopharmaceutics. 26(1). 87–102.
20.
Smith, Edward F., D.E. Griswold, John Egan, et al.. (1993). Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730). European Journal of Pharmacology. 236(3). 477–481.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jie Cai Breakdown of academic impact, for papers by T. Jeroen N. Hiltermann Breakdown of academic impact, for papers by Jan DʼHaese Breakdown of academic impact, for papers by Ming Lu Breakdown of academic impact, for papers by Steven A. Bigler Breakdown of academic impact, for papers by Chikuma Hamada Breakdown of academic impact, for papers by Syed A. Hussain Breakdown of academic impact, for papers by Kouji Izumi Breakdown of academic impact, for papers by Liping Du Breakdown of academic impact, for papers by Nobumichi Tanaka